Redeye updates on Embracer ahead of Q2-results (due November 11) where we expect sequentially strong...
Q3 adjusted EBITDA of EUR 5.5m missed our EUR 6.0m estimate by 8%, with revenue 2% below.
Redeye comments on Freja's Q3 report. ARR was already known from the preliminary figures and landed ...
Redeye provides its review following the release of 4C’s Q3 report, which came in softer than expect...
* Q3 sales and adj. EBITDA 2% below cons, EBIT 3% above * '26e/'27e/'28e adj.
Redeye updates its estimates and valuation following Cheffelo's Q3 2026 report, which we view as str...
CapMan’s Q3 was below our expectations, as fee profit of EUR 3.
Investors House's Q3 report was broadly in line with our expectations, with the Real Estate segment ...
Redeye provides an update following Corline's release of a financial forecast for 2026 and guidance ...
* We leave our estimates broadly unchanged * We expect 31% EBIT growth and strong cash flow in Q4 * ...
* Recovery confirmed as EE volumes ramp * Sales in line, EBIT +19% vs.
In our view, OssDsign’s sales were once again underwhelming.
Cantargia has published an ASH abstract from the investigator-initiated phase Ib/IIa trial of naduno...
Intervacc reports its Q3 report on 12 November. We expect another quiet quarter in terms of sales, w...
Redeye comments on Magle's release of preliminary and unaudited figures for the third quarter of 202...
Alcadon continues to deliver sequential earnings growth, supported by improving market conditions an...
GFT's Q3 should put earnings upside back in focus. Faster growth and improving UK profitability sugg...
* -4%/-2% adj. EBITDA vs ABGSCe/Infront cons in Q3 * Cons.
* EBIT of USD 1.9m, 169% above consensus 0.7m * De-risks estimates for 2027, but not enough to drive...
Redeye comments on the Q3 2026 report from Cheffelo, published this morning.